

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 48065

Title: Precision medicine in gastric cancer

Reviewer's code: 02541859

Reviewer's country: United States

Science editor: Fang-Fang Ji (Quit in 2019)

Reviewer accepted review: 2019-04-22 16:19

Reviewer performed review: 2019-04-22 17:31

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Excellent review. You have mainly mainly discussed about the different chemotherapeutic agent and checkpoint inhibitors. But there are roles of endoscopy and surgery including eradication of H. pylori infection in the management of gastric cancer. It would be great if you could touch on those particularly in conclusion.



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 48065

Title: Precision medicine in gastric cancer

Reviewer's code: 02993121

Reviewer's country: Thailand

Science editor: Fang-Fang Ji (Quit in 2019)

Reviewer accepted review: 2019-04-22 08:19

Reviewer performed review: 2019-04-23 05:57

Review time: 21 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors tried to summarize most of clinical information of gastric cancer. Good review but need more evidences and review as follow: 1. In epidemiology should be summarize as a figure for easy understanding. 2. More information in H. pylori and gastric cancer 3. Proper and new investigations. 4. More review for surgical treatments. 5.



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

AI and gastric cancer eg. robot surgery.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 48065

Title: Precision medicine in gastric cancer

Reviewer's code: 02904061

Reviewer's country: China

Science editor: Fang-Fang Ji (Quit in 2019)

Reviewer accepted review: 2019-04-22 05:26

Reviewer performed review: 2019-04-28 14:49

Review time: 6 Days and 9 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is a review about the Precision medicine in gastric cancer (GC). The author reviewed the progress achieved in the molecular characterization of GC including the application in clinical practice, potential target for the therapy and the advances of target therapy of GC recent years. Gastric cancer is a complicated malignancy. Lots of clinical

trials failed in the decades. This review might offer some clues for the development of target therapy for GC. But there are still some issues need to be revised. 1. Update the data about the incidence and mortality rate of gastric cancer in the “EPIDEMIOLOGY OF GC” part. The data is based on Reference 3 from years 2011 and Reference from years 2005. According to the Global cancer statistics 2018(Bray F, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.), the gastric cancer has been the fifth most frequently diagnosed cancer and the third leading cause of cancer death but not “fourth most malignant tumor in worldwide and the second leading cause of cancer-related deaths” mentioned in the paper. 2. When discuss the EBV-positive tumors in “MOLECULAR CHARACTERIZATION OF GC” part, the term “PDL-1”, “PDL-2” should be corrected as “PD-L1” and “PD-L2”. 3. In the end of page 10, the description “gefitinib and erlotinib, have shown efficacy in EGFR-amplified tumors.” and “Mutations of EGFR confer resistance to these drugs” are inappropriate. These two drugs have been approved as standard first-line therapy for EGFR sensitive mutation patients in non-small cell lung cancer. 4. The paragraphing of each part is not clear enough which is easy to make confusion. For example, in page 9, the description of ACRG classification system was mixed with the description of subtype “CIN”, which is one part of TCGA classification system. The same problem exists in page 11. 5. In the section of “Biomarkers for diagnosis and prediction”, the discussion should focus on gastric cancer. For example, in page 11, the predictive value of TP53 mutation in GC should be mentioned but not just describe its significance in human tumors. 6. In the section discussing target therapy, the clinical evidence is relative insufficient. As a review, the demonstration of the advances should be more comprehensive. For example, for the EGFR signal pathway, TDM-1 is an important agent for anti-HER2 therapy. Although the clinical trial in gastric cancer (GATSBY) was failed, it should be



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

mentioned. Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. A phase I study of pyrotinib in patients with HER2-positive advanced gastric cancer is recruiting. Two phase II clinical trials for Nimotuzumab, which is the first humanized EGFR monoclonal antibody, has been published. Beyond the signal pathway mentioned in this paper, the exploration of parp inhibitor in gastric cancer is ongoing, which is also a promising agent. 7. Increase more context about the outlook and expectations of target therapy in Gastric cancer in the conclusion part. 8. The language need to be more concise

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 48065

Title: Precision medicine in gastric cancer

Reviewer's code: 02941657

Reviewer's country: Thailand

Science editor: Fang-Fang Ji (Quit in 2019)

Reviewer accepted review: 2019-04-23 05:53

Reviewer performed review: 2019-04-29 04:56

Review time: 5 Days and 23 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The author reviewed nowadays clinical molecular target for advance treatment of gastric cancer. On the part of conclusion, the author should add the author's opinion or suggestion on which group of population or stage who should been tested for each target biomarkers. In case of non operable treatment, how the target can be precisely



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

tested.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No